dapagliflozin - NICE guidance for treating chronic heart failure with reduced ejection fraction
Last edited 03/2021 and last reviewed 06/2023
Dapagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
- angiotensin-converting enzyme (ACE) inhibitors or angiotensin-2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
- sacubitril valsartan, with beta blockers, and, if tolerated, MRAs
Start treatment of symptomatic heart failure with reduced ejection fraction with dapagliflozin on the advice of a heart failure specialist. Monitoring should be done by the most appropriate healthcare professional.
Reference:
DAPA HF - analysis of risk of new onset type 2 diabetes in patients with HFrEF
DAPA HF - analysis reveals evidence of benefit of dapagliflozin apparent 28 days post-initiation